The disapp earartce rate of coagulation factors from plasma generally has been determined in normal individuals and in patients suffering from congenital coagulation factor deficiency, but otherwise being healthy. Litde is known about the disappearan ce rate under altered metabolic conditions. During the last few years we have collected data concerning the biological half-life of Factors II, VII, IX and X in hypothyroidism, hyperthyroidism, and during fever. The results seem worth publishing.
Patients
Fifteen normal individuals (members of the staff, average age about 30 years), 10 patients with myxoedema'r, 5 patients with thyreotoxicosis'r-, 5 patients with elevated body temperatures, and 6 "control" patients (patients without fever and with apparently normal thyroid function) are included in this study. Pertinent data concerning the patients are given in Table 1 ,
Methods
Both normal individuals and patients were given a loading dose of 80-100 mg acenocoumarol (Sintrom "Geigy") between 9:00 p.m, and 2:00 a.m., followed by one daily dose of at least 40 mg until the end of the experiment; this high amount of a 4-hydroxycoumarin derivative, approximately ten times the normal mean therapeutic dose, is considered to blod< synthesis of Factors II, VII, IX and X, At the end of the experiment, the effect of acenocoumarol was counteracted, if necessary,by an oral dose of '10 to 30 mg vitamin K, (Konakion 'Rodre"). In the "control" patients and in case of myxoedema, administration of the drug in a therapeutic dose was contintred prophylactically.
'r \fle are irrdebted to Prof. A, Querido, M.D., and his staff, Department of Endocrinology of the University Hospital, Leyden, for their invaluable cooperation. Analysis of coagulation was usually carried out within two hours, and exceptionally as much as six hours after venepuncture. All coagulation tests were performed in ordinary glassware, preheated to 37o C in a warerbath. For the measurement of the "prothrombin' time we used the procedure described originally by Quick (10) . Brain thromboplastin of human origin was prepared according to Owren (9) and stored in small portions ^t -25o C. The normal "prothrombin" time value was 15.1 -f 0.7 seconds.
The activity of Factors II, VII, IX, and X was determined by means of the one-stage procedure as described by us (6) . The substrate plasma for the determination of Factors VII and IX was collected from patients with congenital coagulation factor deficiency, that for the determination of Factors II and X s/as artificially prepared. The large normal range found for Factors II and X in "control" patients ( Fig. 2 and 4) is due to large differences in activity of the different batches of the substrate plasma used. In the Factor IX test, BaSOu-adsorbed oxalated plasma was added to the incubation mixture (6).
In the evaluation of the results of Factor IX. disappearance rate statistical analysis was applied't.
Results
After oral intake of the coumarin drug acenocoumarin) some hours elapse before the activity of Factors II, VII, IX and X starts to decrease and prolongation of the "prothrombin" time commences. This "silent period", which normally lasts 4-8 hours, appears to be shorter in thyreotoxicosis and fever (shortest value 2.5 hours), whereas in myxoedema the beginning of the reaction may occur as late as 15 hours after oral intake. The individual data can be estimated from Figure s l-.4.
The prolongation of the coagulation times appears to take place exponentially (2); straight lines are obtained when the logarithm of the coagulation time is plotted against observation time ( Fig. 1, 2, 3 , and 4). The tangent of the angle between these lines and the X-axis is the parameter for the prolongation rate.
The tangent values for coagulation times ("prothrombin" time as well as coagulation time found in the specific coagulation factor assay system) found in :normal individuals are taken as reference for changes in the disappearance rate .of the coagulation factors in patients. The degree of change is assessed by calculating the ratio, patient's value: normal value. Figure 1 demonstrates the prolongation rate of the "prothrombin" time. In thyreotoxicosis and patients with fever the. rate is clearly increased, whereas in myxoedema it is decreased. The average acceleration in thyreotoxicosis and fever is L.3l and 1..77 times normal, respectivelyi average doubling of the "prothrombin" time takes place after 18 and 1,3.5 hours, respectively, instead of the normal 24 hours. The highest rate is found in a case of sarcoma (i.1054162) with remittent temperatures of up to 40o C; it appears to be about three times normal (Fig. 1, dotted line) , In myxoedema the increase of the "prothrombin" time is retarded on the average to 0.59; doubling of the "prothrombin" time takes place only after about'4L hours, on the ayerage, instead of the normal 24 hours. The longest time required for doubling is 50 hours, whidr correspolrds with a decrease of the prolongation rate to 0. 48 Frorn Figures 2,3 and 4 it can be seen that, regarding the disappearance rate of Factors II, VII and X, similar conclusions are justified. The degree of acceleration and retardation of the prolongation (c. q. disappearance) rarc of the coagulation times (c. q. factors) is calculated by means of the best-fitting regression curves (solid and dotted lines). As far as Factor VII is concerned, the conclusions are evident in all instances, but for Factors II and X only the retardation of the disappearance rate in patients with myxoedema is conclusive; an acceleration seems probable in thyreotoxicosis and during fever; for a more significant result concerning the acceleration of the disappearance rate of Factors II and X in thyreotoxicosis and during fever a longer observation time is needed; a significant acceleration in case of fever has, however, already been demonstrated by one of us (2). F i g. 6 : Disappearance rate of Factor IX in terms of biological half-time (plus 950/o confidence interval) in a male patient, aged 33 years, with continuously strongly elevated body temperature (about 39o C), due to an untreated sarcoma (lab. nr. 311/63). The figures are the result of statistical analysis of the Factor lX-activity, found at the beginning and at the end of the experiment. The decrease of the Factor IX-activity was assumed to have started between 2.5 and 3 hours after oral intake of the loading dose acqpocournarin,
.together with the prolongation of the "prothrombin" time 'Ihe Factor IX activity could not be studied systematically, for tedrnical reasons. Retardation of the disappearance rate of Factor IX was demonstrated in only one patient, suffering from myxoedema, in whom the prolongation rate of the "prothrombin" time was 0.49 times normal (Fig. 5) . The acceleration of the disappearance rare of Facror IX was evident in another patient with fever, in whom the prolongation rate of the "prothrombin" time was 2.4 times normal (Fig. 6) .
The results are presented comprehensively in Table 2 . The degree of retardation and acceleration of the disappearance rate appears to be quite similar whether expressed in terms of prolongation rate of the "prothrombin" time or in terms of the prolongation rate of the coagulation times obtained in the specific one-stage assay.
Table2zTable2isasynopsisoftheresultsobtained.Theprolongationrateofthecoagulation times found in patients is cornpared with those in normal controls and/or "control" patients.
The results are presented as ratiq patient's prolongation rate: normal prolongation rate. Tte figures given under "p. t." ("prothrornbin" time), are more accurate than those under "II", "VII", and "X", because the number of "prothrombin" times has been higher and also the error of determination is considerably lower for the "prothrombin" times than for coagulation times obtained from the assay of the three coagulation factors separately. The fgures given under "II".
"VII", and "X" do not differ significantly from those given under "p. t." droxycoirmarin derivative acenocoumarol (Sintrom "Geigy"). Evidence for blocked synthesis during similar posology *ill be given elsewh ere (2) .
It takes about. 2.5-15 hours before prolongation of the "prothrombin" rime (c. q. decrease of the coagulation factor activity) begins; the shortest intervals ("silent period") between intake of the drug and reaction of the "prorhrombin,, time are found in fever and hyperthyroidism, the longest in myxoedema. Four to eight hours seems to be the normal range.
The prolongation rate of the "prothrombin" time is exponential up to values of about four times normal (2). The mean normal "doubling time,, is 24 hours. In myxoedema the mean is much longer, about 41. hours, the longest ..doubling time" being approximately 50 hours, whereas in hyperthyroidism and fever a marked increase of the prolongation rate is observed. The patients with thyreotoxicosis and fever (the latter having a mean body tempe rature of about 38.20 c) show a mean accelerarion of t.lt and 1.77 rimes, respectively. The shortest "doubling time" was about 8 hours, which corresponds wiih a proio.rgurion rate of about thrice normal; this concerned a patient with high body temperature due to a necrotizing malignant lymphoma. Since the longest ..doubling tile" in a case of myxoedema was about 50 hours, the fastest and slowest prolongation rate of the "prothrombin" time differ by a factor of at least 6. It is most interesting in this respect that the shortest and longest ..silent period,, also differ by a {actor of about 6.
The prolongation rate of the Factor Vll-coagulation time shows a clear-cut correspondence with the prolongation rate of the "prothrombin,, time in all instances. The values for Factors II and X behave similarly, the correlation being most evident in myxoedema.
_ .considering the prolongation rate of coagulation times as parameter of the biological disappearance rate of coagulation factors, the latter )pp" r, to be far from constantl decrease to about 0.5 times normal and increase up to three times the normal rate can occur.. Alterations in the biological disappe arance rate under pathological conditions occur in other coagulation factors besides Facrors II, VII, and X. Concerning Factor IX we think an increased disappearance rare during fever has been proven by studies made during substitution therapy in haemophilia B (5) and is further demonstrated by the data in Fig. 6 ; a decrease of th" Factor IX-disappearance rate was found in one of our myxoedema cases (Fig. 5) . Factor VIII appears to be more rapidly consumed in patients after surgical treatment (g). The disappearance rate of fibrinogen was observed to be increased in a case of complete liver dystrophy accompanied by elevated body temperatures (4); on the other hand, significant retardation of consumption has been demonstrated in myxoedema (3). Serum albumin, in severe illness, apPears to decay considerably faster than is normally rhe case (1). In fact, such changes seem to be a nonspecific phenomenon inherent in protein metabolism itself' ' Th.'."nre-of the alterations-in metabolic activity of coagulation factors in myxoedema, thyreotoxicosis, and fever is as yet unknown' Thyroxin should be co.rsidered as one of the possible pathogenetic agents. Animal experiments may teadr us more (7) .
The practical consequences of large differences in the metabolic decay of the .org,rlution factors .orr.",,,"d i" this study are at 1911 twofold' Firstly' in coumarin treatment, therapeutic hypocoagulability will be readred in patients with high fevers up to thr:ee times larfiei that in afebrile patients' whereas in hypothyroidism it will take much longer than is normally the case. This is of ,i".irt i*porru.r." in relation to co-bined heparin/coumarin treatment: heparin must be administered until the activity of Factors IX and X is between 10 and 25o/o of normal. Hence, in patients *ith ,ror-ul metabolic activity' the minimal ;;r;r;
of heparin therapy will be 4_5 days; hypothyroid patients musr be t,reatedfo, -or" than aweet; with elevated body temperatures, however, 2 days of heparin will often be sufficient. secondly, for substitution therapy in christ-,,,u, iir.ur", the minimum amount of Factor IX needed for safe haemostasis, i' e' for the mainrenance of a 25olo level, will vary gready with changes in the prri"rrr,, metabolic acti:Vity, up to three times the amount calculated from the normal disappearance tate of Factor IX will be needed. If the aetiology of the accelerated disappearance of coagulation factors were known, specific inh-ibitors could be used to drastically ,i-p[ry substitution thetapy in christmas disease, and in other coagulation factor deficiencies'
SummarY
The biological disappearance fate of coagulation factors II, vII, IX and X frorn plasma"is decrea's"d ir, -y"oedema and'increased in thyreotoxicosis' In patienis with elevated body temperatures, an increase of up to three times the normal rate was observed. The ciinical implications of these findings are briefly discussed.
R6sum6
La vitesse de disparition des facteurs de coagulation II, VII, IX et X est diminu6e "r, .", d'hyiothyr6oidie et acc6l6r6e en cas d'hyperthyr6oidie' La vitesse p"", err" acc1l;r6e'1.rrq,r;l trois fois la normale diez des malades fi6vreux' Les cmiquences de ces rdsultats sont de grande importance dans le traitement aux enticoagulants er pendant la substitution chez I'hdmophile par du plasma frais ar des prdparations concentr6es de facteurs de coagulation.
Zusammenfassung
Die biologische Halbwertszeit der Gerinnungsfaktoren II, vII, IX und X ist im Blut von Myxcidempatienren vermindert und im Falle von Hyperthyreoidie -erhciht. Bei fieberhaften Zustdnden kann der dreifache lflert der Norm erreicht werden. Die Folgerungen dieser Befunde ftir die Klinik werden kurz diskutiert.
